The Department of Defense (DOD) announces the FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award, focusing on supporting clinical trials aimed at improving treatment and management of Amyotrophic Lateral Sclerosis (ALS). This funding opportunity will allocate approximately $6.6 million to support around two pilot clinical trial applications, with a direct cost cap of $2 million for each project. The application process involves a two-step submission: a pre-application due by June 6, 2025, followed by a full application due on August 27, 2025. Eligible applicants include both intramural and extramural organizations, with no cost-sharing required. Applicants must focus on either biomarker-driven interventions or improvements in clinical care. Trials that integrate community collaborations to enhance research impact are mandated. Key elements for successful applications include demonstrating study readiness, regulatory compliance, and plans for patient recruitment and retention. Upon selection, the research teams are expected to start their clinical trials within 12 to 18 months post-award, enhancing the understanding and treatment of ALS, particularly in relation to military populations. This initiative reflects the DOD's commitment to addressing the health needs of service members and their families affected by ALS.